3-amino-3-pyridin-3-yl-acrylonitrile | 55330-45-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-amino-3-pyridin-3-yl-acrylonitrile
• 英文别名: 3-Amino-3-(pyridin-3-yl)prop-2-enenitrile；3-amino-3-pyridin-3-ylprop-2-enenitrile
• CAS: 55330-45-5
• 化学式: C₈H₇N₃
• 分子量: 145.164
• InChiKey: LYVMPDNCWIHLDR-UHFFFAOYSA-N

物化性质

• 熔点：
  104-106 °C
• 沸点：
  412.3±33.0 °C(Predicted)
• 密度：
  1.170±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-amino-3-pyridin-3-yl-acrylonitrile 在 一水合肼 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 生成 5-Pyridin-3-yl-3-(4-trifluoromethyl-phenylamino)-1H-pyrazole-4-carbonitrile
  参考文献：
  名称：

  Pyrazole Bioisosteres of Leflunomide as B-Cell Immunosuppressants for Xenotransplantation and Chronic Rejection:  Scope and Limitations

  摘要：

  T-cell immunosuppressant-based therapies efficiently control early graft rejection in allotransplantation settings. They fail, however, to prevent those rejection events which are mediated by transplant-induced antibody (Ab) responses such as those involved in xenograft and chronic allograft rejection. This is mainly due to their inability to block T-cell-independent Ab production against the transplanted organs. The bioactive metabolite 2(Z) of leflunomide (1) inhibits the formation of such Ab, but the drug has pharmacokinetic properties and a therapeutic window incompatible with transplantation indications. Pyrazole 3, a constrained analogue of 2(Z), was designed and shown to be conformationally and biologically similar to 2(Z). Further investigations with derivatives of 3 demonstrated that the pyrazoles had very tight structure-activity relationships, the only equipotent compound being 3o. However, in contrast to 2(Z), both 3 and 3o were inactive in vivo due to short half-life and drug concentrations lower than the in vitro obtained IC50 values, Compound 3o inhibits T-cell-independent Ab production by a different biochemical mechanism from that of 2(Z) and 3 and may therefore represent a valuable tool for the identification of new targets for B-cell inhibition.

  DOI：

  10.1021/jm981028c

文献信息

• 5-isothiazolamine derivatives
  申请人：Akzo N.V.

  公开号：US05179110A1

  公开（公告）日：1993-01-12

  The invention relates to 5-isothiazolamine derivatives having the formula ##STR1## in which R.sub.1 is hydrogen, methyl, or ethyl, R.sub.2 and R.sub.3 are independently selected from hydrogen and alkyl, and the dotted line represents an optional bond, or a pharmaceutically acceptable acid addition salt thereof. The compounds have .alpha..sub.2 -adrenergic agonistic properties with little cardiovascular side-effects and minimal or no dopaminergic and cholinergic activity.

  本发明涉及具有以下式子的5-异噻唑胺衍生物：##STR1## 其中R.sub.1为氢、甲基或乙基，R.sub.2和R.sub.3分别选自氢和烷基，点线表示可选键，或其药学上可接受的酸加成盐。该化合物具有α2-肾上腺素能激动剂特性，且心血管副作用小，最小或无多巴胺能和胆碱能活性。
• 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists
  申请人：Crespo Crespo Maria Isabel

  公开号：US20080058356A1

  公开（公告）日：2008-03-06

  4-Aminopyrimidine derivatives of formula (I) FORMULA heteroaryl groups, including pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are adenosine A 2A receptor antagonists useful in the treatment of movement disorders such as Parkinson's disease.

  公式（I）的4-氨基嘧啶衍生物，其中包括杂环基团，以及其药学上可接受的盐，其中R1和R2是阿多诺西嗪A2受体拮抗剂，适用于治疗运动障碍，如帕金森病。